{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:05:08Z","timestamp":1790719508704,"version":"4.1.0"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antimicrobial-resistant infections are commonly encountered in US hospitals and result in significant morbidity and mortality. This guidance document provides recommendations for the treatment of infections caused by extended-spectrum \u03b2-lactamase\u2013producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated common questions regarding the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Based on review of the published literature and clinical experience, the panel provide recommendations and associated rationale for each recommendation. Because of significant differences in the molecular epidemiology of resistance and the availability of specific anti-infective agents globally, this document focuses on treatment of antimicrobial-resistant infections in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Approaches to empiric treatment selection, duration of therapy, and other management considerations are briefly discussed. The majority of guidance focuses on preferred and alternative treatment recommendations for antimicrobial-resistant infections, assuming that the causative organism has been identified and antibiotic susceptibility testing results are known. Treatment recommendations apply to both adults and children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The field of antimicrobial resistance is dynamic and rapidly evolving, and the treatment of antimicrobial-resistant infections will continue to challenge clinicians. This guidance document is current as of 17 September 2020. Updates to this guidance document will occur periodically as new data emerge. Furthermore, the panel will expand recommendations to include other problematic gram-negative pathogens in future versions. The most current version of the guidance including the date of publication can be found at www.idsociety.org\/practice-guideline\/amr-guidance\/.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1478","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T15:18:44Z","timestamp":1600960724000},"page":"e169-e183","source":"Crossref","is-referenced-by-count":433,"title":["Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and\n                    <i>Pseudomonas aeruginosa<\/i>\n                    with Difficult-to-Treat Resistance (DTR-\n                    <i>P. aeruginosa<\/i>\n                    )"],"prefix":"10.1093","volume":"72","author":[{"given":"Pranita D","family":"Tamma","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L","family":"Aitken","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Medical Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, University Hospitals Cleveland Medical Center and Department of Medicine, Pharmacology, Molecular Biology, and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J","family":"Mathers","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pathology, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius J","family":"Clancy","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"2021040811224588700_CIT0001","author":"World Health Organization","year":"2019"},{"key":"2021040811224588700_CIT0002","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"2021040811224588700_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz089","article-title":"The Infectious Diseases Society of America\u2019s 10 \u00d7 \u201820 initiative (10 new systemic antibacterial agents US Food and Drug Administration approved by 2020): is 20 \u00d7 \u201820 a possibility?","volume":"69","author":"Talbot","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11908-019-0690-9","article-title":"Recognizing and overcoming resistance to new beta-lactam\/beta-lactamase inhibitor combinations","volume":"21","author":"Ho","year":"2019","journal-title":"Curr Infect Dis Rep"},{"key":"2021040811224588700_CIT0005","first-page":"1803","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0006","doi-asserted-by":"crossref","first-page":"ofz344","DOI":"10.1093\/ofid\/ofz344","article-title":"Estimating the treatment of carbapenem-resistant Enterobacteriaceae infections in the United States using antibiotic prescription data","volume":"6","author":"Clancy","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021040811224588700_CIT0007","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1473-3099(20)30153-5","article-title":"Needs assessment for novel gram-negative antibiotics in US hospitals: a retrospective cohort study","volume":"20","author":"Strich","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021040811224588700_CIT0008","article-title":"Languid uptake of ceftazidime-avibactam for carbapenem-resistant gram-negative infections and continued reliance on polymyxins","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0009","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciz1040","article-title":"Charting the path forward: development, goals and initiatives of the 2019 Infectious Diseases of America strategic plan","volume":"69","author":"Sears","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2021040811224588700_CIT0011","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0012","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"2021040811224588700_CIT0013","doi-asserted-by":"crossref","first-page":"ofz353","DOI":"10.1093\/ofid\/ofz353","article-title":"Molecular epidemiology of ceftriaxone non-susceptible Enterobacterales isolates in an academic medical center in the United States","volume":"6","author":"Tamma","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021040811224588700_CIT0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/jtm\/taw102","article-title":"The ecology of extended-spectrum \u03b2-lactamases (ESBLs) in the developed world","volume":"24","author":"Doi","year":"2017","journal-title":"J Travel Med"},{"key":"2021040811224588700_CIT0015","doi-asserted-by":"crossref","first-page":"e00047-e19","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of beta-lactamase-producing pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2021040811224588700_CIT0016","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0017","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.01896-13","article-title":"Contemporary diversity of \u03b2-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent \u03b2-lactamase groups","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0018","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/JCM.01687-08","article-title":"Unreliable extended-spectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates","volume":"47","author":"Robberts","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2021040811224588700_CIT0019","volume-title":"M100 Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute","year":"2020","edition":"30"},{"key":"2021040811224588700_CIT0020","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"key":"2021040811224588700_CIT0021","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1001\/archinte.167.20.2207","article-title":"Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women","volume":"167","author":"Gupta","year":"2007","journal-title":"Arch Intern Med"},{"key":"2021040811224588700_CIT0022","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.293.8.949","article-title":"Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial","volume":"293","author":"Hooton","year":"2005","journal-title":"JAMA"},{"key":"2021040811224588700_CIT0023","doi-asserted-by":"crossref","first-page":"e02165-18","DOI":"10.1128\/AAC.02165-18","article-title":"A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0024","doi-asserted-by":"crossref","first-page":"e00749-17","DOI":"10.1128\/mBio.00749-17","article-title":"Widespread fosfomycin resistance in gram-negative bacteria attributable to the chromosomal fosA gene","volume":"8","author":"Ito","year":"2017","journal-title":"mBio"},{"key":"2021040811224588700_CIT0025","doi-asserted-by":"crossref","first-page":"e00634-19","DOI":"10.1128\/JCM.00634-19","article-title":"The role of fosA in challenges with fosfomycin susceptibility testing of multispecies Klebsiella pneumoniae carbapenemase-producing clinical isolates","volume":"57","author":"Elliott","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2021040811224588700_CIT0026","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2021040811224588700_CIT0027","author":"Procter and Gamble Pharmaceuticals, Inc"},{"key":"2021040811224588700_CIT0028","author":"US Food and Drug Administration"},{"key":"2021040811224588700_CIT0029","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2021040811224588700_CIT0030","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia","volume":"179","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2021040811224588700_CIT0031","doi-asserted-by":"crossref","first-page":"ofz364","DOI":"10.1093\/ofid\/ofz364","article-title":"Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs. beta-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis","volume":"6","author":"Punjabi","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021040811224588700_CIT0032","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/AAC.37.4.851","article-title":"Kinetic interactions of tazobactam with beta-lactamases from all major structural classes","volume":"37","author":"Bush","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0033","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0034","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jac\/dks088","article-title":"Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?","volume":"67","author":"Livermore","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2021040811224588700_CIT0035","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2147\/IDR.S166790","article-title":"Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals","volume":"11","author":"Zhou","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2021040811224588700_CIT0036","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QCO.0000000000000623","article-title":"Current evidence for therapy of ceftriaxone-resistant gram-negative bacteremia","volume":"33","author":"Paterson","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2021040811224588700_CIT0037","doi-asserted-by":"crossref","first-page":"ofw132","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2021040811224588700_CIT0038","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0039","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0040","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0041","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2003.11.007","article-title":"In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae","volume":"49","author":"Burgess","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021040811224588700_CIT0042","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1469-0691.2007.01846.x","article-title":"Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide","volume":"14 Suppl 1","author":"Drieux","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2021040811224588700_CIT0043","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1128\/JCM.02130-10","article-title":"Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae","volume":"49","author":"Garrec","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2021040811224588700_CIT0044","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.2015.12480","article-title":"Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012\u20132013","volume":"314","author":"Guh","year":"2015","journal-title":"JAMA"},{"key":"2021040811224588700_CIT0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0046","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021040811224588700_CIT0047","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/cid\/ciw398","article-title":"High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-\u03b2-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center","volume":"63","author":"Aitken","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0048","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.diagmicrobio.2018.10.004","article-title":"Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016","volume":"93","author":"Senchyna","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021040811224588700_CIT0049","doi-asserted-by":"crossref","first-page":"e01140-18","DOI":"10.1128\/JCM.01140-18","article-title":"Phenotypic detection of carbapenemase-producing organisms from clinical isolates","volume":"56","author":"Tamma","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2021040811224588700_CIT0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12941-016-0155-z","article-title":"In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates","volume":"15","author":"Sutherland","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2021040811224588700_CIT0051","doi-asserted-by":"crossref","first-page":"e00313-18","DOI":"10.1128\/AAC.00313-18","article-title":"In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0052","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0053","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021040811224588700_CIT0054","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"2021040811224588700_CIT0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021040811224588700_CIT0056","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021040811224588700_CIT0057","author":"Shionogi, Inc"},{"key":"2021040811224588700_CIT0058","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jinf.2019.06.011","article-title":"Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: dose is critical","volume":"79","author":"Sorl\u00ed","year":"2019","journal-title":"J Infect"},{"key":"2021040811224588700_CIT0059","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0060","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0061","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0062","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2021040811224588700_CIT0063","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0064","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0065","doi-asserted-by":"crossref","first-page":"e02313-19","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0066","doi-asserted-by":"crossref","first-page":"e00672-19","DOI":"10.1128\/AAC.00672-19","article-title":"Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae","volume":"63","author":"Canver","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0067","doi-asserted-by":"crossref","first-page":"ftz040","DOI":"10.1093\/femspd\/ftz040","article-title":"Imipenem\/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center","volume":"77","author":"Kulengowski","year":"2019","journal-title":"Pathog Dis"},{"key":"2021040811224588700_CIT0068","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"2021040811224588700_CIT0069","doi-asserted-by":"crossref","first-page":"e00174","DOI":"10.1128\/AAC.00174-18","article-title":"Relebactam is a potent inhibitor of the KPC-2 beta-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae","volume":"62","author":"Papp-Wallace","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0070","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0071","doi-asserted-by":"crossref","first-page":"e00989","DOI":"10.1128\/AAC.00989-17","article-title":"Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity","volume":"61","author":"Nelson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0072","doi-asserted-by":"crossref","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0073","doi-asserted-by":"crossref","first-page":"ofx101","DOI":"10.1093\/ofid\/ofx101","article-title":"Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature","volume":"4","author":"Shields","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2021040811224588700_CIT0074","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0075","doi-asserted-by":"crossref","first-page":"115012","DOI":"10.1016\/j.diagmicrobio.2020.115012","article-title":"In vitro activity of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacilli isolated from patients in Canadian intensive care units","volume":"97","author":"Golden","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021040811224588700_CIT0076","doi-asserted-by":"crossref","first-page":"e01968-17","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0077","doi-asserted-by":"crossref","first-page":"e00093","DOI":"10.1128\/AAC.00093-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0078","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"},{"key":"2021040811224588700_CIT0079","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"2021040811224588700_CIT0080","first-page":"ii25","article-title":"Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies","volume":"68 Suppl 2","author":"Eckmann","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021040811224588700_CIT0081","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41 Suppl 5","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0082","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/138920009787048356","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline","volume":"10","author":"Falagas","year":"2009","journal-title":"Curr Drug Metab"},{"key":"2021040811224588700_CIT0083","doi-asserted-by":"crossref","first-page":"e02125-17","DOI":"10.1128\/AAC.02125-17","article-title":"Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0084","doi-asserted-by":"crossref","first-page":"e01951-19","DOI":"10.1128\/AAC.01951-19","article-title":"Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018","volume":"64","author":"Castanheira","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0085","doi-asserted-by":"crossref","first-page":"e01045-17","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0086","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021040811224588700_CIT0087","doi-asserted-by":"crossref","first-page":"e02463-18","DOI":"10.1128\/AAC.02463-18","article-title":"Successful treatment of bacteremia due to NDM-1-producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy","volume":"63","author":"Hobson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0088","doi-asserted-by":"crossref","first-page":"e01426-19","DOI":"10.1128\/AAC.01426-19","article-title":"Searching for the optimal treatment for metallo- and serine-beta-lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0089","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/jac\/dkz495","article-title":"Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime\/avibactam","volume":"75","author":"Sieswerda","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021040811224588700_CIT0090","doi-asserted-by":"crossref","first-page":"105842","DOI":"10.1016\/j.ijantimicag.2019.10.023","article-title":"Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime\/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases","volume":"55","author":"Benchetrit","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021040811224588700_CIT0091","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2021040811224588700_CIT0092","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"2021040811224588700_CIT0093","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.02744-13","article-title":"In vitro activity of plazomicin against 5015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011\u20132012","volume":"58","author":"Walkty","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0094","doi-asserted-by":"crossref","first-page":"e0139836","DOI":"10.1371\/journal.pone.0139836","article-title":"Antibiotic resistance of Pseudomonas aeruginosa in pneumonia at a single university hospital center in Germany over a 10-year period","volume":"10","author":"Yayan","year":"2015","journal-title":"PLoS One"},{"key":"2021040811224588700_CIT0095","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1128\/AAC.00402-12","article-title":"Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms","volume":"56","author":"Neuner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0096","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2018.11.021","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015\u20132017) isolates from hospitalized patients with pneumonia in US medical centers","volume":"94","author":"Carvalhaes","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021040811224588700_CIT0097","doi-asserted-by":"crossref","first-page":"ofz240","DOI":"10.1093\/ofid\/ofz240","article-title":"Comparison of the in vitro susceptibility of ceftolozane-tazobactam with the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aeruginosa from ICU patients with bloodstream infections or pneumonia","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021040811224588700_CIT0098","doi-asserted-by":"crossref","first-page":"e02165-19","DOI":"10.1128\/AAC.02165-19","article-title":"Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic beta-lactam-resistant mutants","volume":"64","author":"Fraile-Ribot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0099","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0100","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021040811224588700_CIT0101","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0102","article-title":"RESTORE-IMI 2: randomised, double-blind, phase III trial comparing efficacy and safety of imipenem\/cilastatin (IMI)\/relebactam (REL) versus piperacillin\/tazobactam (PIP\/TAZ) in adult patients with hospital-acquired or ventilator-associated bacterial pneumonia (HABP\/VABP)","author":"Titov","journal-title":"European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)"},{"key":"2021040811224588700_CIT0103","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0104","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021040811224588700_CIT0105","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0106","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02085-18","article-title":"Deciphering the evolution of cephalosporin resistance to ceftolozane-tazobactam in Pseudomonas aeruginosa","volume":"9","author":"Barnes","year":"2018","journal-title":"mBio"},{"key":"2021040811224588700_CIT0107","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance","author":"Tamma","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0108","author":"US Food and Drug Administration"},{"key":"2021040811224588700_CIT0109","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1586\/14787210.5.5.811","article-title":"Polymyxin B: similarities to and differences from colistin (polymyxin E)","volume":"5","author":"Kwa","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2021040811224588700_CIT0110","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/cid\/cit453","article-title":"Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center","volume":"57","author":"Akajagbor","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021040811224588700_CIT0111","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/AAC.02476-13","article-title":"In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy","volume":"58","author":"Phe","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0112","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijantimicag.2013.12.002","article-title":"Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium","volume":"43","author":"Tuon","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2021040811224588700_CIT0113","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/AAC.02634-15","article-title":"Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B","volume":"60","author":"Rigatto","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021040811224588700_CIT0114","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.diagmicrobio.2009.07.018","article-title":"Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity","volume":"65","author":"Oliveira","year":"2009","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1478\/35087329\/ciaa1478.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/7\/e169\/36985429\/ciaa1478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/7\/e169\/36985429\/ciaa1478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T07:24:43Z","timestamp":1617866683000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/7\/e169\/5940736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":114,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,10,27]]},"published-print":{"date-parts":[[2021,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1478","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,10,27]]}}}